BBIO Form 144: Charles J Homcy sold 250k shares; 50k more planned ($2.4M)
Rhea-AI Filing Summary
BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000. The filing shows 191,168,504 shares outstanding.
The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer and paid for in cash. The filing also discloses three sales by Charles J Homcy on 08/08/2025 totaling 250,000 common shares with gross proceeds of $6,907,905, $2,302,295 and $2,302,220 (combined $11,512,420).
Positive
- Transaction details are fully disclosed, including broker, acquisition date, origin as founders' shares, and payment method (cash).
- Recent sale proceeds are itemized, providing clear dollar amounts and dates for investor review.
Negative
- Significant insider monetization occurred: three sales on 08/08/2025 totaling 250,000 shares for $11,512,420 in gross proceeds.
- An additional planned sale of 50,000 shares (aggregate market value $2.4M) is disclosed, which increases near-term share supply from related parties.
Insights
TL;DR: Recent large share dispositions and an additional planned sale are disclosed; impact appears transactional rather than company-specific.
The filing documents a proposed sale of 50,000 shares valued at $2.4M and prior sales totaling 250,000 shares for approximately $11.51M. These amounts are explicit and sizeable in dollar terms but represent small percentages of the reported 191.17M shares outstanding. From a market-impact perspective, the disclosure signals notable insider monetization in the near term; however, the filing contains no operational or financial performance details to suggest a material change to the companys fundamentals.
TL;DR: The filer documents founder-origin shares and multiple recent sales; disclosure is complete but raises typical governance questions about insider liquidity.
The record shows the shares to be sold were acquired as founders' shares on 07/01/2019 and paid for in cash, indicating long-held positions being liquidated. The filing names Charles J Homcy as the seller for recent transactions on 08/08/2025. This Form 144 provides required transparency under Rule 144; it does not include commentary on any trading plans or other governance arrangements that might contextualize the sales.